• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

    63.23 -3.17 (-4.77%)
    Streaming Delayed Price Updated: 3:43 PM EDT, Oct 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 71,482
    Open 65.69
    Bid (Size) 61.98 (1)
    Ask (Size) 64.35 (1)
    Prev. Close 66.40
    Today's Range 62.88 - 69.72
    52wk Range 21.10 - 79.02
    Shares Outstanding 11,834,361
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Large Patient Population Is Key Driver For Bright Minds' Growth
    BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potential and key Phase 2 data expected by the end of 2025 
    Via Benzinga
    Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside
    Chardan initiates Bright Minds with a Buy rating, citing over $1 billion sales potential for epilepsy drug BMB-101 despite limited clinical data. 
    Via Benzinga

    Performance

    YTD
    +53.8%
    +53.8%
    1 Month
    +39.2%
    +39.2%
    3 Month
    +143.3%
    +143.3%
    6 Month
    +91.0%
    +91.0%
    1 Year
    +119.5%
    +119.5%

    More News

    Read More
    Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
    From Bright Minds Biosciences
    Via GlobeNewswire
    Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
    From Bright Minds Biosciences
    Via GlobeNewswire
    Biotechs on the Brink: 2 Stocks With Huge Potential
    Via MarketBeat
    This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
    From Bright Minds Biosciences
    Via GlobeNewswire
    Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
    From Bright Minds Biosciences
    Via GlobeNewswire
    Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
    Via The Motley Fool
    Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
    From Bright Minds Biosciences
    Via GlobeNewswire
    EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
    Via Benzinga
    Topics Government
    What's Going On With Bright Minds Biosciences Stock?
    Via Benzinga
    Topics Artificial Intelligence
    Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
    From Bright Minds Biosciences
    Via GlobeNewswire
    MarketBeat Week in Review – 10/14 - 10/18
    Via MarketBeat
    Topics Artificial Intelligence Economy
    Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results
    Via Benzinga
    What's Going On With Bright Minds Biosciences Stock Friday?
    Via Benzinga
    Dow Falls Over 100 Points; Netflix Posts Upbeat Results
    Via Benzinga
    Topics Stocks
    Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis
    Via Benzinga
    Topics Artificial Intelligence
    Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF
    Via AB Newswire
    Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views
    Via Benzinga
    Topics Stocks
    Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
    From Bright Minds Biosciences
    Via GlobeNewswire
    US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results
    Via Benzinga
    Bright Minds Biosciences Stock Surges Almost 1,500%
    Via MarketBeat
    Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
    From Bright Minds Biosciences
    Via GlobeNewswire

    Frequently Asked Questions

    Is Bright Minds Biosciences Inc. - common stock publicly traded?
    Yes, Bright Minds Biosciences Inc. - common stock is publicly traded.
    What exchange does Bright Minds Biosciences Inc. - common stock trade on?
    Bright Minds Biosciences Inc. - common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Bright Minds Biosciences Inc. - common stock?
    The ticker symbol for Bright Minds Biosciences Inc. - common stock is DRUG on the Nasdaq Stock Market
    What is the current price of Bright Minds Biosciences Inc. - common stock?
    The current price of Bright Minds Biosciences Inc. - common stock is 63.23
    When was Bright Minds Biosciences Inc. - common stock last traded?
    The last trade of Bright Minds Biosciences Inc. - common stock was at 10/17/25 03:43 PM ET
    What is the market capitalization of Bright Minds Biosciences Inc. - common stock?
    The market capitalization of Bright Minds Biosciences Inc. - common stock is 748.29M
    How many shares of Bright Minds Biosciences Inc. - common stock are outstanding?
    Bright Minds Biosciences Inc. - common stock has 748M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.